A Phase 2, Randomized, Placebo-Controlled Study To Evaluate Safety, Tolerability, And Efficacy Of Tak-079 In Patients With Generalized Myasthenia Gravis
Posted Date: Mar 5, 2021
- Investigator: Hani Kushlaf
- Specialties:
- Type of Study: Drug
This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of TAK-079 in patients with generalized myasthenia gravis (MG) in combination with standard background therapy.
Criteria:
Generalized Mg Positive Anti–Acetylcholine Receptor (Achr) Or Anti–Muscle-Specific Tyrosinekinase (Musk) Antibodies, Class Ii To Iv Disease According To The Myasthenia Gravis Foundation Of America (Mgfa), And A Myasthenia Gravis-Activities Of Daily Living (Mg-Adl) Score Of 6 Or Higher.
Keywords:
Mg
For More Information:
Elizabeth Gehlmann
513-558-4497
gehlmaem@ucmail.uc.edu